Mirabilis Completes First Human Trial Of Non-Invasive Treatment For Uterine Fibroids

Main Category: Women's Health / Gynecology
Also Included In: Clinical Trials / Drug Trials;  Pregnancy / Obstetrics
Article Date: 01 May 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


Mirabilis Medica, a privately-held medical device company, announced completion of its first human trial, which served as a preliminary demonstration of clinical feasibility of its prototype High Intensity Focused Ultrasound (HIFU) system for treatment of uterine fibroids. Volunteer patients were treated with the Mirabilis system just prior to scheduled hysterectomies, after which the excised uterine tissue was examined by a pathologist for effects of treatment. This analysis demonstrated successful creation of lesions within the target zone.

"We are encouraged by this early clinical feedback, which is an important milestone in Mirabilis' path to developing a commercial product. We continue to develop several advanced features in preparation for future efficacy studies in patients with fibroids," said Mirabilis CEO Mike Connolly.

About Uterine Fibroids

Fibroids are extremely common benign tumors of the uterus which can substantially impact quality of life. Symptoms can include heavy or prolonged menstrual bleeding, pelvic cramps, urinary frequency or urgency, and pregnancy loss or infertility. An estimated 25% of women (16 million in the U.S.) suffer fibroid symptoms at some point in their life, leading to 250,000 annual U.S. hysterectomies - a highly invasive surgery with many side effects.

About Mirabilis Medica

Mirabilis Medica, based in Bothell WA, was founded in 2004 by Michael Lau, M.D., FACS, FACOG, Alexander Lebedev, and Shahram Vaezy, Ph.D. Mirabilis' patented technology combines the application of therapeutic ultrasound (i.e. HIFU) under real-time guidance of imaging ultrasound. This leading-edge technology is designed to allow a physician to treat pathological tissue deep inside the body without incisions, punctures or other damage to intervening tissue.

Mirabilis Medica

Article adapted by Medical News Today from original press release.
Visit our women's health / gynecology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Mirabilis Medica. "Mirabilis Completes First Human Trial Of Non-Invasive Treatment For Uterine Fibroids." Medical News Today. MediLexicon, Intl., 1 May. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/105879.php>

APA
Mirabilis Medica. (2008, May 1). "Mirabilis Completes First Human Trial Of Non-Invasive Treatment For Uterine Fibroids." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/105879.php.

Please note: If no author information is provided, the source is cited instead.


Women's Health / Gynecology

Most Popular Articles



Follow Our Women's Health News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Women's Health / Gynecology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »